The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Hypertriglyceridemia is an important risk factor for cardiovascular disease. Elevated plasma very low-density lipoprotein (VLDL) puts insulin-resistant patients at risk for atherosclerosis. VLDL readily induces macrophage lipid accumulation and inflammatory responses, for which targeted therapeutic strategies remain elusive. We examined the ability of VLDL to induce macrophage foam cells and the inflammatory response and sought to define the cell signaling cascades involved. We further examined the potential of peroxisome proliferator-activated receptor (PPAR) δ activation to attenuate both VLDL-stimulated lipid accumulation and cytokine expression. Methods and Results-THP-1 macrophages exposed to VLDL displayed significant triglyceride accumulation, which was attenuated by PPARδ activation. PPARδ agonists stimulated a transcriptional program resulting in inhibition of lipoprotein lipase activity, activation of fatty acid uptake, and enhanced β-oxidation. VLDL-treated macrophages significantly increased the expression of activator protein 1 associated cytokines interleukin-1β, macrophage inflammatory protein 1α, and intercellular adhesion molecule-1. VLDL treatment significantly increased the phosphorylation of both extracellular signal-related kinase 1 and 2 and p38. VLDL reduced AKT phosphorylation as well as its downstream effector forkhead box protein O1, concomitant with increased nuclear forkhead box protein O1. Cells treated with PPARδ agonists were completely resistant to VLDL-induced expression of inflammatory cytokines, mediated by normalization of mitogenactivated protein kinase (MAPK) erk and AKT/forkhead box protein O1 signaling.
E xcessive lipid accumulation within macrophages of the arterial intima drives the synthesis and secretion of proinflammatory mediators, potentiating atherogenesis. 1 Canonically, elevated plasma low-density lipoprotein (LDL) is considered the major lipoprotein contributing to accelerated atherogenesis. However, epidemiological evidence strongly suggests that hypertriglyceridemia also increases the risk of premature atherosclerosis, especially in the context of metabolic syndrome and type 2 diabetes mellitus. 2, 3 Plasma triacylglycerol (TG)-carrying very low-density lipoprotein (VLDL) has been localized within atherosclerotic lesions from human patients and animal models, 4, 5 providing rationale for examining the mechanisms by which these lipoproteins induce the development of macrophage foam cells. VLDL readily induces macrophage lipid accumulation, [6] [7] [8] which in turn stimulates the synthesis of cytokines such as interleukin (IL)-1β and macrophage inflammatory protein (MIP)-1α. [9] [10] [11] The mechanisms regulating these lipid-induced macrophage inflammatory responses have not been fully characterized.
In mouse macrophages, VLDL-induced expression of MIP-1α requires fatty acid liberation by lipoprotein lipase (LPL) and is dependent on the activation of extracellular signalrelated kinase 1 and 2 (ERK1/2). 9 Furthermore, VLDL potentiates lipopolysaccharide (LPS)-stimulated macrophage IL-1β secretion via activation of the transcription factor activator protein (AP)-1, 10 which is known to be regulated by mitogen-activated protein (MAP) kinases ERK1/2 and p38. 12 The involvement of p38, which is thought to act cooperatively with ERK1/2 in AP-1 associated inflammatory responses, 12 has not been established. 9 In addition, macrophage insulin resistance may potentiate the inflammatory response. Macrophagespecific deletion of the insulin receptor in Ldlr −/− mice significantly increased atherosclerosis, 13 an effect attributed to impaired macrophage AKT/forkhead box protein O1 (FoxO1) signaling. 13 Insulin-resistant macrophages with cholesterolinduced endoplasmic reticulum-stress display impaired AKT phosphorylation, increased nuclear FoxO1 activity, and enhanced apoptosis. 14 Furthermore, IL-1β is a FoxO1 target gene in macrophages with insulin resistance. 15 Collectively, these studies highlight the importance of examining the role of AKT/FoxO1 signaling in the VLDL-induced inflammatory response.
The peroxisome proliferator-activated receptors (PPARs) are important regulators of metabolic and inflammatory signaling. 16 The 3 known isoforms, namely PPARα, PPARγ, and PPARδ, each exhibit distinct tissue distribution and PPAR-specific regulation of gene transcription. 16 In contrast to PPARα and PPARγ, expression of PPARδ is ubiquitous, with high levels in macrophages, 17 where its biological role is unclear. Macrophage PPARδ is activated by VLDL-derived fatty acids, 18, 19 and conflicting reports have demonstrated that synthetic ligands promote either lipid accumulation 17 or fatty acid catabolism. 18, 19 Consequently, the net effect of PPARδ activation on VLDL-induced TG accumulation is unknown. The anti-inflammatory properties of PPARδ activation have been linked to the liberation of B cell lymphoma 6 from unliganded PPARδ, 20 which inhibits expression of AP-1-inducible cytokines by localizing to AP-1 response elements and recruiting corepressors to these promoter regions. 21 Additionally, in adipocytes and cardiomyocytes, PPARδ agonists inhibit LPSinduced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) regulated cytokine expression. 22, 23 The mechanism(s) underlying VLDL-induced cytokine expression in macrophages, in the absence of LPS, and the impact of PPARδ activation have not been elucidated.
In the present study, we report that synthetic ligand activation of PPARδ attenuates VLDL-stimulated TG accumulation by activating a transcriptional program resulting in attenuation of LPL activity, increased fatty acid uptake, and enhanced β-oxidation. VLDL stimulates the expression of proinflammatory cytokines IL-1β, MIP-1α, and intercellular adhesion molecule (ICAM)-1 via both ERK1/2-and AKT/FoxO1dependent signaling mechanisms. Furthermore, macrophage treatment with synthetic PPARδ ligands inhibits proinflammatory cytokine expression, by inhibiting VLDL-stimulated ERK1/2 activation and reversing VLDL-mediated inhibition of AKT/FoxO1 phosphorylation.
Methods
An expanded Materials and Methods section is available in the online-only Data Supplement.
Lipoproteins
Subjects were recruited from the Lipid Clinic at the London Health Sciences Center University Campus (London, Ontario, Canada). The University of Western Ontario Health Science Standing Committee on Human Research approved the studies (IRB reference #15685). VLDL (Sf 20 to 400) was isolated from plasma of type IV hyperlipoproteinemic patients by differential ultracentrifugation using a Beckman 70.1 Ti rotor (16 hours, 146 682 × g 12°C) as previously described. 8
Cell Culture and Analyses
Human THP-1 macrophages were obtained from American Type Culture Collection (Manassas, VA) and cultured as described previously. 24 PPARδ agonists GW0742 (Sigma) and GW501516 (Alexis Biochemicals, Plymouth, PA) were dissolved in dimethyl sulfoxide (Sigma) and incubated with cells at the indicated concentrations. THP-1 macrophages were preincubated (24 hours) in the presence or absence of PPARδ agonists. Subsequently, cells were incubated with PPARδ agonists in the presence or absence of lipoproteins or various inhibitors as indicated. Assays to determine PPARδ agonist dose-responses, cellular lipid mass, LPL activity, fatty acid uptake, fatty acid β-oxidation, TG synthesis, and luciferase activity were performed as described in the online-only Data Supplement.
Quantitative Real-Time Polymerase Chain Reaction and Immunoblotting
Total RNA was isolated from cells and specific mRNA abundances measured by quantitative real-time polymerase chain reaction (PCR) using an ABI Prism (7900HT) Sequence Detection System (Applied Biosystems, Foster City, CA). 24 Cell lysates were fractionated into cytosolic and nuclear fractions, and proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted with specific antibodies as described previously. 24 Protein levels were determined by densitometry. 24
Statistical Analyses
Data are expressed as mean±SEM. Significances of differences were determined using 1-way ANOVA followed by Bonferroni or Tukey posthoc analysis where indicated. Significance thresholds were P<0.05.
Results

PPARδ-Specific Activation Attenuates VLDL-Induced Macrophage Triacylglycerol Accumulation
THP-1 cells treated with VLDL demonstrated a dose-dependent increase in TG mass achieving a marked 5-fold increase with VLDL at 50 µg/mL ( Figure 1A and 1B). Pretreatment with PPARδ agonists for 24 hours modestly but significantly reduced VLDL-induced TG mass by 25% to 30% ( Figure 1A and 1B). VLDL significantly induced intracellular free fatty acid mass, which was unchanged by pretreatment with PPARδ agonists ( Figure 1C ). Cellular cholesteryl ester or free cholesterol concentrations were unaffected by VLDL or PPARδ agonists ( Figure 1D ), indicating that whole particle VLDL uptake was modest. A known PPARδ-specific target gene, adipocyte differentiation-related protein, 18 was significantly increased by both agonists ( Figure 1E ), indicating PPARδ activation.
High doses of PPAR agonists can activate PPAR isoforms nonselectively. 25, 26 Therefore, we determined the PPARδspecificity of the concentrations of agonists used. PPARδdeletion results in derepression of PPARδ target genes, 19 and transrepression of inflammatory cytokine expression, creating an experimental confounder for the present studies. 20 We therefore assessed agonist-specificity by cotransfecting HepG2 cells with luciferase reporter constructs driven by PPAR response elements and each PPAR isoform (α, γ, δ). We determined dose-responses for each receptor in cells treated with PPARδ agonists (GW0742 and GW501516), and used agonists for PPARα (GW7647) and PPARγ (rosiglitazone) as positive controls. GW0742 at 25 nmol/L and GW501516 at 100 nmol/L were concentrations at which these ligands maximally activated PPARδ, without activation of either PPARα or PPARγ (Figure IA-ID in the online-only Data Supplement). Furthermore, canonical PPARα and PPARγ target genes (ACOX and FABP4, respectively) were unaffected by either 25 nmol/L GW0742 or 100 nmol/L GW501516 ( Figure  IE and IF in the online-only Data Supplement). Although unlikely, these agonists may have effects on non-PPAR targets. However, with respect to PPARs, these data demonstrate selectivity of the agonist concentrations used for PPARδ.
PPARδ Agonists Regulate LPL Activity, Fatty Acid Uptake, and Fatty Acid β-Oxidation
We examined whether PPARδ activation attenuated VLDLinduced TG mass by regulating lipoprotein hydrolysis, fatty acid uptake, or fatty acid esterification. In contrast to rosiglitazone, LPL mRNA was unchanged in response to PPARδ agonists, further demonstrating PPARδ-specificity ( Figure 2A ; Figure Figure 1 . Peroxisome proliferator-activated receptor (PPAR) δ-specific activation attenuates very low-density lipoprotein (VLDL)-induced triacylglycerol mass accumulation. THP-1 cells were preincubated with PPARδ agonists GW0742 and GW501516 for 24 hours, followed by a 16-hour incubation with or without VLDL (50 μg-TC/mL). A and B, Triacylglycerol (TG) mass (n=5-7). C, Free fatty acid (FFA) mass (n=3-4). D, Cholesteryl ester (CE) and free cholesterol (FC) mass (n=6). E, Adipocyte differentiation-related protein (ADRP) mRNA in THP-1 cells after preincubation with PPARδ agonists for 24 hours, and after a 16-hour incubation, with or without VLDL (n=4). Data are presented as mean±SEM. Different letters indicate significant differences; ANOVA with posthoc Tukey test (P<0.05). * indicates significant difference vs dimethyl sulfoxide (DMSO) control; ANOVA with post hoc Bonferroni test (P<0.05). December 2012 potently inhibit LPL activity. 27 Angiopoietin-like 4 mRNA expression was markedly enhanced by both PPARδ agonists in the presence or absence of VLDL, which was associated with a 50% inhibition of LPL activity ( Figure 2B and 2C). The PPARδ ligands significantly increased expression of the PPAR-target gene CD36 28 irrespective of lipid load, which was correlated with a 25% increase in palmitate uptake, but not oleate uptake ( Figure 2D-2F ). DGAT1 mRNA, DGAT2 mRNA, and TG synthesis were unaffected by PPARδ activation ( Figure II in the online-only Data Supplement). PPARδ ligands significantly upregulated CPT-1α mRNA, with or without VLDL, which was associated with a 40% increase in fatty acid oxidation ( Figure 2G and 2H). Collectively, these results indicate that although PPARδ activation modestly increases palmitate uptake, attenuated LPL-mediated VLDL TG-hydrolysis and increased fatty acid β-oxidation results in a net reduction of macrophage triglyceride content.
PPARδ Agonists Inhibit VLDL-and Free Fatty Acid-Induced Cytokine Expression
Exposure of mouse macrophages to VLDL stimulates MIP-1α expression, an AP-1-mediated inflammatory response. 9 
Inhibition of VLDL-Induced Inflammation by PPARδ Activation Is Independent of Reduced Cellular Triglyceride
We examined whether inhibition of VLDL-induced inflammation by PPARδ agonists was a consequence of reduced TG accumulation. Complete inhibition of LPL with tetrahydrolipstatin blocked cellular TG and cytokine expression. However, inhibition of TG accumulation with low-dose tetrahydrolipstatin, to the same extent as that achieved by PPARδ agonists (≈25%), decreased ICAM-1 expression by 30% but did not affect MIP-1α or IL-1β ( Figure V in the online-only Data Supplement). PPARδ activation normalized VLDL-induced cytokine expression, even when β-oxidation was inhibited by etomoxir ( Figure 3D ), a CPT-1α inhibitor. 29 These data suggest that increased β-oxidation only partially accounts for reduced cytokine expression by PPARδ activation.
Our results are consistent with the concept that VLDLderived FAs are the primary mediators of the inflammatory response. 9, 30 Paradoxically, FAs also activate PPARδ. 18 To reconcile this, macrophages were treated with oleic acid, which resulted in a marked induction of TG mass and expression of IL-1β and MIP-1α ( Figure VIA and VIB in the online-only Data Supplement). These effects were significantly attenuated by preincubation of cells with GW501516 ( Figure VIA and VIB in the online-only Data Supplement), suggesting that the ability of FAs to activate PPARδ 18 is insufficient to prevent macrophage TG accumulation and cytokine expression.
VLDL-Stimulated Expression of Inflammatory Cytokines Is Dependent on MAPK Activation and Repression of AKT/FoxO1 Signaling
VLDL-induced MIP1-α expression in mouse macrophages involves activation of ERK1/2. 9 In THP-1 cells, ERK1/2 phosphorylation increased significantly within 0.5 hour of VLDL exposure, which returned to baseline by 1 hour ( Figure 4A ; Figure IVC in the online-only Data Supplement). Similarly, VLDL-stimulated p38 phosphorylation, reaching peak phosphorylation by 0.5 hour, and remained elevated for ≈3 hours ( Figure 4B ). The MAP ERK kinase 1/2 inhibitor, U0126, abrogated VLDL-stimulated expression of all cytokines ( Figure 4C ). In contrast, the p38 inhibitor SB203580 stimulated cytokine expression under basal conditions and further increased cytokine expression in VLDL-treated cells ( Figure 4D ). Inhibition of p38 resulted in a 5-fold induction in ERK1/2 phosphorylation ( Figure VIIA in the online-only Data Supplement), suggesting that the mitogen-activated protein kinase (MAPK) erk signal stimulates cytokine expression, whereas MAPK p38 represses the actions of MAPK erk .
The temporal disconnect between VLDL-induced MAPK erk activation/deactivation (1 hour) and elevated cytokine expression (16 hours) suggests that other macrophage inflammatory signaling pathways are stimulated by VLDL. Given that IL-1β is a target of nuclear FoxO1 in macrophages in the context of insulin resistance, 15 we examined the role of AKT/FoxO1 in VLDL-induced inflammation. Exposure of THP-1 cells to VLDL resulted in a time-dependent reduction of phospho-AKT levels for up to 6 hours ( Figure 5A ). Reduced phospho-AKT was correlated with attenuated phospho-FoxO1 and increased nuclear FoxO1 by 3 hours (Figure 5B and 5C), demonstrating that VLDL inhibits AKT/FoxO1 signaling. As proof-of-concept, treatment of macrophages with AKT inhibitor IV mimicked VLDL treatment, resulting in reduced phospho-AKT, reduced phospho-FoxO1 ( Figure VIIB in the online-only Data Supplement) and significant elevations in the expression of IL-1β as well as MIP-1α and ICAM-1 ( Figure 5D ).
VLDL-Stimulated Activation of MAPK Signaling and Repression of AKT/FoxO1 Signaling Are Corrected by PPARδ Activation
To determine the mechanism whereby PPARδ activation attenuates VLDL-induced cytokine expression, we examined the effect of PPARδ agonists on macrophage MAPK and AKT/ FoxO1 signaling. GW0742 and GW501516 significantly attenuated both VLDL-stimulated ERK1/2 and p38 activation ( Figure  6A and 6B) . Inhibition of β-oxidation by etomoxir had no effect on the ability of PPARδ activation to normalize VLDL-induced MAPK signaling ( Figure VIIIA and VIIIB in the online-only Data Supplement). In control cells, GW0742 and GW501516 increased both phospho-AKT and phospho-FoxO1 ( Figure IXA in the online-only Data Supplement). Importantly, both PPARδ agonists completely reversed the VLDL-induced reductions in phospho-AKT and phospho-FoxO1, and prevented the increase in nuclear FoxO1 (Figure 6C-6E ). Etomoxir treatment had no effect on PPARδ agonist-induced normalization of AKT/ FoxO1 signaling ( Figure VIIIC and VIIID in the online-only Data Supplement). Collectively, these data demonstrate that PPARδ activation inhibits VLDL-induced inflammatory cytokine expression by inhibiting MAPK signaling and restoring signaling through AKT/FoxO1. Furthermore, the modulation of both signaling pathways by PPARδ activation was independent of PPARδ agonist-induced β-oxidation.
Discussion
Patients with insulin-resistant syndromes such as type 2 diabetes mellitus and metabolic syndrome have significant elevations of plasma VLDL, which confers increased risk for atherosclerosis. 3, 31 Type 2 diabetes mellitus, metabolic syndrome, and atherosclerosis are interwoven by the commonality of chronic low-grade inflammation. 32, 33 However, the molecular processes that link elevated plasma VLDL, atherosclerosis, and inflammation require further elucidation. In the present study, we demonstrate that human native VLDL induces both macrophage TG accumulation and expression of proinflammatory cytokines, in the absence of exogenous LPS. Furthermore, we demonstrate that PPARδ activation attenuates both of these pathogenic macrophage foam cell processes and define the mechanisms involved. Although VLDL-derived fatty acids are the stimulus for cytokine expression, the ability of PPARδ agonists to dampen the inflammatory response is independent of agonist-induced LPL inhibition, stimulation of β-oxidation, or reduction in cellular TG.
PPARδ is expressed in abundance in macrophages, 17 but its biological role in lipid homeostasis has been controversial. [17] [18] [19] In this study, we demonstrate that VLDL-induced TG Hydrolysis of VLDL-TG by macrophage LPL is required for cellular FA uptake and TG resynthesis. 6 PPARδ agonists increased angiopoietin-like 4 expression, which was coupled to a reduction in LPL activity, thereby limiting liberated FAs for macrophage uptake. These findings are consistent with recent studies demonstrating that angiopoietin-like 4 is a PPARδ target gene, which is expressed in macrophages and irreversibly inactivates LPL by converting active LPL-dimers into inactive LPL-monomers. 27, 34 PPARδ activation increased expression of the FA transporter CD36, which resulted in a modest increase in FA uptake, albeit from a smaller FA pool. However, we confirm that PPARδ agonists upregulate CPT-1α expression, 19 which enhances FA oxidation. Furthermore, we show for the first time that PPARδ activation results in a net depletion of VLDL-induced TG accumulation. These results are consistent with the concept that one role for PPARδ activation in macrophages is to prevent lipotoxicity by limiting VLDL hydrolysis and enhancing FA catabolism 18, 19 and contradict the notion that PPARδ activation promotes lipid accumulation. 17 Furthermore, although VLDL-derived FAs activate PPARδ, 18 potent synthetic agonists of PPARδ are required to attenuate VLDL-stimulated macrophage foam cell formation as well as inhibit the inflammatory response. VLDL markedly stimulates expression of AP-1-inducible inflammatory cytokines, which occurs in the absence of NF-κB signaling or exogenous LPS. VLDL has been demonstrated to induce MIP-1α in murine macrophages via ERK1/2 activation. 9 We extend this response to human THP-1 macrophages and to include the induction of IL-1β and ICAM-1. In THP-1 macrophages, both ERK1/2 and p38 are activated in response to VLDL, and p38 phosphorylation remains elevated well beyond that of ERK1/2. Inhibition of p38 stimulated ERK1/2 phosphorylation and enhanced cytokine expression. Moreover, the combination of VLDL treatment and p38 inhibition results in additive stimulation of cytokine expression over either treatment alone, suggesting that relieving the p38induced impediment on ERK1/2 signaling enhances cytokine expression. Although in some cells, p38 activation has no effect or amplifies ERK1/2 signaling, we and others have reported that in hepatoma cells, insulin-induced phosphorylation of p38 also acts as a negative regulator of insulin-stimulated ERK1/2 activation. 35, 36 The present study supports this paradigm and demonstrates for the first time that VLDL-stimulation of macrophage cytokine expression through MAPK erk involves p38 acting as a negative regulator of ERK1/2 signaling. VLDL-treated macrophages displayed attenuated AKT and FoxO1 phosphorylation, which coincided with increased nuclear FoxO1 and increased cytokine expression. Although the mechanism by which VLDL attenuates AKT signaling leading to activation of FoxO1 has not been defined, it is known that FoxO1 is a direct transcriptional activator of IL-1β in mouse macrophages. 15 Several reports indicate that lipid-induced macrophage insulin resistance is associated with impaired AKT/FoxO1 signaling, increased FoxO1 activity, and thus plays a critical role in macrophage inflammation and endoplasmic reticulum-stress-induced apoptosis. [13] [14] [15] Some studies have suggested that free fatty acids induce macrophage inflammation through activation of toll-like receptor signaling. 37, 38 However, more recent reports have provided contrary evidence. 30, 39 The present study is consistent with the concept that VLDL-stimulated macrophage inflammatory cytokine expression results from macrophage insulin resistance, rather than elicitation of a toll-like receptor-NFκB response. This is evidenced by the following: (1) impaired AKT/FoxO1 signaling and enhanced MAPK signaling by VLDL treatment, (2) canonical NF-κB target genes TNFα and IL-6 being unaffected by VLDL treatment, and (3) the inability of parthenolide (an inhibitor of NFκB signaling) to block VLDL-stimulated expression of IL-1β, MIP-1α, and ICAM-1. It is tempting to hypothesize that VLDL-induced inflammatory responses are initially derived from rapid ERK1/2 activation followed by later and sustained AKT signaling. The ERK1/2 signal is rapidly downregulated by activated p38, whereas the AKT signal is possibly mitigated by a self-limiting feedback loop. 40 Furthermore, with time, it is possible that incoming FAs increase the saturated lipid content of the ER membrane, thereby inducing an endoplasmic reticulum-stress response, 41 and subsequent amplification of nuclear FoxO1. 42 The exact relationship among time-dependent signaling events governing VLDL-stimulated inflammatory responses requires further study.
VLDL-induced expression of inflammatory cytokines was completely normalized by both PPARδ agonists, despite a lack of effect on intracellular free fatty acid levels, and even under conditions of inhibited β-oxidation. This suggests that stimulation of β-oxidation by PPARδ activation is insufficient to explain the anti-inflammatory effects. Additionally, VLDL-stimulated phosphorylation of both ERK1/2 and p38 were normalized by PPARδ activation, suggesting regulation of a common upstream MAPK factor. This concept is consistent with a previous report that GW0742 inhibited angiotensin II-induced phosphorylation of ERK1/2 and p38 in mouse macrophages, via upregulation of RGS4 and RGS5. 43 Whether this mechanism applies to the present study remains to be determined.
Macrophages exposed to VLDL in the presence of PPARδ agonists restored levels of phospho-AKT, phospho-FoxO1, and nuclear FoxO1 to those observed in untreated cells, an effect independent of PPARδ agonist-induced enhanced β-oxidation. Although modulation of AKT activity by PPARδ activation has been observed, 44, 45 et al 45 reported that GW501516-treated endothelial progenitor cells displayed marked elevations in phospho-AKT, without increased integrin-like kinase expression. In our experiments, PPARδ agonists increased phospho-AKT and phospho-FoxO1, without effecting integrin-like kinase or 3-phosphoinositidedependent kinase 1 expression ( Figure IX in the online-only Data Supplement). This suggests that the anti-inflammatory effect of PPARδ activation is, in part, attributable to direct stimulation of AKT/FoxO1 phosphorylation, thereby preventing VLDL from dysregulating this signaling cascade. In summary, VLDL-induced macrophage lipid accumulation and proinflammatory cytokine synthesis are attenuated by PPARδ activation, effects which involve ERK1/2-and AKTdependent signaling mechanisms. These combined reductions of lipid accumulation and inflammatory cytokine expression by PPARδ ligands reveal a novel mechanism for preventing the deleterious consequences of macrophage foam cell formation. 
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